NCT03491748View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

September 11, 2019

Study Completion Date

September 11, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

ETX0282

Oral Gelatin capsules

DRUG

Cefpodoxime proxetil

Oral tablets

DRUG

Placebo

Oral Gelatin capsules

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Entasis Therapeutics

INDUSTRY

NCT03491748 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants | Biotech Hunter | Biotech Hunter